Atlas Trials

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Clinical trial NCT02802423 · NOT_YET_RECRUITING

Trial details

NCT number
NCT02802423
Sponsor
BioLite, Inc.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2027-01-01
Primary completion
2028-04-30
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.